## Core Concept
Denileukin diftitox is a recombinant protein used in the treatment of certain types of cancer. It works by selectively targeting and killing malignant cells. This drug is an example of a targeted therapy.

## Why the Correct Answer is Right
Denileukin diftitox, also known as Ontak, is a fusion protein that combines interleukin-2 (IL-2) with a diphtheria toxin fragment. It is specifically used to treat **cutaneous T-cell lymphoma (CTCL)**, particularly in patients who have not responded to previous therapies. The IL-2 part of the fusion protein binds to IL-2 receptors on the surface of certain T cells, and the diphtheria toxin fragment then enters the cells and inhibits protein synthesis, leading to cell death.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because denileukin diftitox is not primarily used for treating breast cancer.
- **Option B:** This option is incorrect as it does not accurately represent the primary use of denileukin diftitox.
- **Option C:** This option might seem plausible but is incorrect because denileukin diftitox is specifically indicated for cutaneous T-cell lymphoma, not for a broad category like "hematological malignancies" in general without specification.
- **Option D:** This option is incorrect because denileukin diftitox is not used for treating ovarian cancer.

## Clinical Pearl / High-Yield Fact
A key point to remember is that denileukin diftitox is used in the treatment of **cutaneous T-cell lymphoma (CTCL)**, making it a valuable option for patients with this specific condition who have not responded to other treatments. Its mechanism of action involves targeting cells that express the IL-2 receptor, making it a targeted therapy.

**Correct Answer: C. Cutaneous T-cell lymphoma.**